PT  - JOURNAL ARTICLE
AU  - Julie Vialard-Miguel
AU  - Agnès Georges
AU  - Joaquim Mazère
AU  - Dominique Ducassou
AU  - Jean-Benoît Corcuff
TI  - <sup>131</sup>I in Blood Samples: A Danger for Professionals? A Problem for Immunoassays?
DP  - 2005 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - 172--174
VI  - 33
IP  - 3
4099  - http://tech.snmjournals.org/content/33/3/172.short
4100  - http://tech.snmjournals.org/content/33/3/172.full
SO  - J. Nucl. Med. Technol.2005 Sep 01; 33
AB  - Objective: Our objective was to investigate the safety of radioactive blood samples from patients receiving 131I and whether the radioactivity affects the validity of assays. Methods: First, the activity of samples from patients given 131I was measured by 3 methods and compared with the upper threshold. Then, pilot sera were spiked with 131I, and possible interference was investigated using 2 immunoradiometric assays. Results: The activity of 13 of the 15 samples was below the European limit; the other 2 samples were from patients with reduced renal clearance rates. No differences in thyroglobulin level or thyroid-stimulating hormone level were found between sera that were spiked with 131I and sera that were not. Conclusion: These blood samples are safe because they contain negligible activity, and the use of radioimmunoassays or immunoradiometric assays on them produces reliable results.